US/UK/Canada

Share

Contacts

  • Mark Waugh

    CEO


    +1 (260) 804-1342

    • Links

    Pick a time period -
    Tags ( Active)

    OssDsign announces remarkable real-world results with 88.4% fusion rate in a highly complex patient cohort from the spinal fusion registry PROPEL

    Uppsala, June 26, 2025. OssDsign AB (publ.) today announces that the company has published one-year results from the first 108 patients in its prospective, multi-center, spinal fusion registry PROPEL. The results show an outstanding fusion rate of 88.4% in the real-world setting in a highly complex patient cohort, demonstrating that OssDsign Catalyst® shows strong performance even in challenging patient populations with high BMI, previous failed fusion surgeries, smokers, multi-level procedures and several comorbidities.“Typically, I would expect to see dramatically lower fusion rates for

    OssDsign reaches its target of 300 patients enrolled in the prospective spinal fusion registry PROPEL

    Uppsala, February 25, 2025. OssDsign AB (publ.) today announced that the company has reached its target of 300 enrolled patients in the multi-center, prospective spinal fusion registry PROPEL. This registry, initiated in March 2022, collects real-world data from patients treated with OssDsign Catalyst."When we initiated the PROPEL registry, we communicated a target of 300 patients. Reaching this milestone already confirms our capability to gather clinically relevant data and the successful enrollment is a direct result of surgeons' high interest in collaborating with OssDsign to evaluate

    OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL

    Uppsala, August 16, 2023. OssDsign AB (publ.) today announces that the company has enrolled 200 patients in the multi-center, prospective spinal fusion registry, PROPEL. The registry was initiated in March 2022, to gather real-world data from patients who have been treated with OssDsign Catalyst."This important milestone reflects our ability to collect clinically relevant data and is a direct result of the high level of interest from surgeons to continue using OssDsign Catalyst, resulting in a growing number of patients being included in PROPEL. The collection of robust clinical evidence is

    First Post-Market Safety Report on OssDsign Catalyst shows zero percent device related complication rate

    Uppsala, November 17, 2022. OssDsign AB (publ.) today announces data from the first post-market safety report of the company's innovative product OssDsign Catalyst, that stimulates bone growth in spinal fusion. The report, which covers the time from product launch in August 2021 until August 31, 2022, did not record any device related complaints nor device related adverse events.OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. Similar to the body’s own bone mineral structure, the patented nanocrystalline

    OssDsign reaches milestone of 100 patients in its PROPEL registry ahead of time

    Uppsala, November 9, 2022. OssDsign AB (publ.) today announces that the company has reached the milestone of 100 patients in the multi-centre, prospective spinal fusion registry, PROPEL. The registry was initiated in March 2022, to gather real-world data from patients who have been treated with OssDsign Catalyst.During 2022, clinics have gradually enrolled patients to the PROPEL registry, with the objective to evaluate the use and outcome of OssDsign Catalyst in a real-world clinical practice. The primary endpoint of the study is measuring the rate of spinal fusion, using computer

    OssDsign enrolls the first patient to the multi-center prospective spinal fusion registry PROPEL in the U.S.

    Uppsala, April 4, 2022. OssDsign AB (publ.) today announces that the first patient has been enrolled to the company’s multi-center, prospective spinal fusion registry in the U.S., PROPEL, with the objective to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.The patient recruitment follows on the March 18 initiation of the first clinical site in PROPEL, a spinal fusion registry that initially will evaluate the rate of fusion, twelve months following treatment with the company’s nanosynthetic bone graft, OssDsign Catalyst. Additionally, the clinical safety

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media